Drug Trial Radar · NCT02596126
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,499
Actual
Start
Jul 2016
Primary completion
Oct 31, 2021
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Charite University, Berlin, Germany; Centre Hospitalier Universitaire de Besancon; Wroclaw Medical University; Semmelweis University; General University Hospital, Prague; Servicio Madrileño de Salud, Madrid, Spain; London School of Hygiene and Tropical Medicine; Ferrer Internacional S.A.; Istituto Di Ricerche Farmacologiche Mario Negri
- First posted
- Nov 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the local clinical practices at each participating country) in secondary prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in elderly patients with a recent myocardial infarction.
Conditions
- Myocardial Infarction
- Cardiovascular Disease
Interventions
Cardiovascular PolypillDrug
Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril. Participants will receive one of the following cardiovascular polypill: (A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg). or (B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
Treatment Prevention for Secondary CVDrug
ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Cardiovascular Adverse Events (MACE)Time frame: Up to 5 years
Locations
113 sites in 7 countries. Site status is shown where the registry gives one.
Nemocnice Rudolfa a Stefanie Benešov
Benešov, Czechia
Nemocnice Jihlava
Jihlava, Czechia
Krajská necmonice Liberec
Liberec, Czechia
Fakultní nemocnice Olomouc
Olomouc, Czechia
Nemocnice Slaný
Slaný, Czechia
Nemocnice Podlesí
Třinec, Czechia
Všeobecná fakultní nemocnice v Praze
Prague, Prague, Czechia
Fakultní nemocnice Královské Vinohrady
Prague, Praha 10, Czechia
Nemocnice Na Homolce
Prague, Praha 5, Czechia
Centre Hospitalier Universitaire d'Angers
Angers, France
Centre Hospitalier Régional Universitaire de Besançon
Besançon, France
Centre Hospitalier Universitaire de Lyon
Bron, France
Centre Hospitalier Universitaire de Caen
Caen, France
Centre Hospitalier Metropole Savoie
Chambéry, France
Centre Hospitalier Universitaire Henri Mondor
Créteil, France
Centre Hospitalier Universitaire de Dijon
Dijon, France
Centre Hospitalier Universitaire de Grenoble
Grenoble, France
Centre Hospitalier Régional et Universitaire de Lille
Lille, France
Centre Hospitalier St Joseph St Luc
Lyon, France
Centre Hospitalier Universitaire de Nice
Nice, France
Hôpital Bichât
Paris, France
Centre hospitalier Universitaire de Bordeaux
Pessac, France
Centre Hospitalier Universitaire de Toulouse
Toulouse, France
GLG Fachklinik Wolletzsee GmbH
Angermünde, Germany
AVK Vivantes Rehabilitation GmbH
Berlin, Germany
DRK- Kliniken Berlin/ Köpenick
Berlin, Germany
Maria Heimsuchung Caritas-Klinik Pankow
Berlin, Germany
Jüdisches Krankenhaus
Berlin, Germany
Charité - Universitätsmedizin Berlin, Centrum für Schlaganfallforschung (CSB)
Berlin, Germany
Vivantes Humboldt Klinikum
Berlin, Germany
Vivantes Klinikum Spandu
Berlin, Germany
DRK Klinik Berlin Westend
Berlin, Germany
GK Havelhöhe
Berlin, Germany
Gesundheitszentrum Bitterfeld /Wolfen GmbH
Bitterfeld-Wolfen, Germany
Mediclin Reha-Zentrum Spreewald Fachklinik für innere Medizin
Burg, Germany
MediClin Herzzentrum Coswig
Coswig, Germany
Klinik am See, Rehabilitationszentrum für innere Medizin
Rüdersdorf, Brandenburg, Germany
Immanuel Klinikum Bernau Herzzentrum Brandenburg
Bernau, State of Berlin, Germany
Medical Park Berlin Humboldtmühle
Tegel, State of Berlin, Germany
Brandenburgklinik Berlin-Brandenburg GmbH, Haus Brandenburg/ Kardiologie
Waldsiedlung, State of Berlin, Germany
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.